At all measurement points, outcome will be assessed by means of questionnaires which are sent to the participants by mail three days earlier.
The primary end-point outcomes recommended by these international experts include headache days with moderate or severe intensity, migraine days, or frequency of migraine episodes.
End point outcomes for 18 participants (5 %) were unavailable because they were reported as lost to follow up (n = 11) or dead (n = 7) during the clinical trial.
For the two-point outcomes (binary), the rank of the attributes on the choice of Test A and Test B was consistent across models.
In the present study, patients were followed up for the primary end-point outcomes, (all-cause mortality and cardiovascular mortality), in order to identify the relationship between plasma glucose concentrations and the apoptosis marker sFas upon admission and at the first end-point outcome after acute STEMI.
Study selection Randomised and non-randomised studies comparing enoxaparin with unfractionated heparin during percutaneous coronary intervention and reporting on both mortality (efficacy end point) and major bleeding (safety end point) outcomes.
For the three-point outcomes (nominal and bivariate) in which the choices of Test A, Test B and opt-out were estimated simultaneously, the attributes were ranked consistently: cost, sensitivity, specificity, process, preparation and pain.
At each stated follow up point, outcomes will be compared using multivariate regression based methods (e.g. logistic or least squares) adjusting follow up scores for baseline scores (where available) and key baseline characteristics (e.g. age/sex, race/ethnicity).
However, as this pilot study was not powered for adjusted comparisons of single time-point outcomes, these results were only reported for descriptive purposes and were not tested for statistical significance.
Patients were assessed at 1 year radiographically, clinically and with a custom 100-point outcome measure that included pain, function and motion.
